Future of e-marketing in focus in Philadelphia

Share this article:
Pharmaceutical e-marketing experts called for more innovation in online efforts as the Web enters its second and third incarnations. “We need to add what is changing to our planning process,” said Paul Ivans, president, Evolution Road Consulting. “Strategic and tactical planning must include innovation.” Ivans was among a number of online experts to address 250 e-marketers at IIR's 6th Annual ePharma Summit in Philadelphia yesterday. Topics of discussion included the rise of the empowered consumer, growth of user generated content and new ways to drive ROI. Jack Barrette, category development officer - lifestyles, health & medicine, Yahoo!, said marketers need to think outside the banner when devising their ad strategies. “Creative strategy needs to be much more than banner ads” Barrette said. “We need to engage folks in advertising differently.” However, Thomas Mangano, assistant VP, consumer communications & e-business at Wyeth, warned e-marketers not be too hasty to hop on the Web 2.0 bandwagon simply for technology's sake. “Pharmaceutical marketing does not necessarily have to be on the leading edge. These are not lifestyle products we are selling." According to Mangano, pharma's audiences tend to be older and later adopters of technology, unlike target audiences of beverage companies and automakers. “We need to facilitate to the right audience at the right time…not just be online and doing things.” Monday afternoon's closing session featured a thought leader panel discussion including e-marketers from Genentech, Novartis, Lilly and Wyeth. The panel discussed some of the ways e-marketers can enhance the consumer experience in their e-marketing efforts to help them further drive ROI. “A great Web site user experience will result in the holy grail of better patient outcomes and high ROI," said Frank Visconti, associate director, marketing, at Novartis. Ben Lei, senior manager, e-marketing at Genentech said that information needs to be easier for consumers to find. “We need to remove the clutter,” Lei said. Amy Chafin, specialty therapeutic area marketing manager at Lilly said her firm is working on finding the right marketing mix through an integration of “sales force, e-detailing, mobile technology and word-of-mouth marketing.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...